Aura Biosciences, Inc. Deferred Costs, Noncurrent
Aura Biosciences, Inc. (AURA) had Deferred Costs, Noncurrent of $1.58 million as of 2021-09-30, per its 10-Q filed 2021-11-24.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredCosts · last filed 2021-11-24
- 2021-09-30: Deferred Costs, Noncurrent $1.58M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2021-09-30 | $1.58M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |